Cancer

Title
Study Comparing Radiation Therapy With or Without Trastuzumab in Women With Early Stage Breast Cancer
Trial Number
202083081909
Number of Participants
2,000
Principal Investigator

Shelly Lo

M.D., ABIM
Hematology/Oncology
Associate Professor
Eligibility

Adult females = 18 years old with the following six criteria:
1) Tumor must be histologically ductal carcinoma in situ, 2) ECOG performance status of 0 or 1, 3) DCIS must be HER2-positive as determined by central testing, 4) All DCIS must have been resected by lumpectomy, 5) Margins of the resected specimen must be histologically free of DCIS and 6) the interval between the last surgery for excision of DCIS and randomization must be no more than 120 days.

Purpose

This purpose of this study is to find out if adding trastuzumab to breast radiation therapy is more effective than radiation therapy without trastuzumab in preventing occurrence of breast cancer in the same breast, in the other breast or in other parts of the body in patients with early stage breast cancer.

Enrollment

(708) 327-3154

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.